title: Report of the American Heart Association (AHA) Scientific Sessions 2015, Orlando.
abstract: The American Heart Association Scientific Sessions were held in Orlando on November 7-15, 2015. The meeting attracted more than 18,000 participants, including physicians, research scientists, students, and paramedical personnel, from more than 100 countries. Sessions over the 5 days included a comprehensive and unparalleled education delivered via more than 5,000 presentations, with 1,000 invited faculty members and 4,000 abstract presentations from the world leaders in cardiovascular disease. It also displayed the newest cardiovascular technology and resources by more than 200 exhibitors. There were 19 trials scheduled in 6 late-breaking clinical trial sessions. The Systolic Blood Pressure Intervention Trial (SPRINT) aimed to determine the most appropriate targets for the systolic blood pressure among persons without diabetes. A total of 9,361 persons with systolic blood pressure of ≥130 mmHg and an increased cardiovascular risk, but without diabetes, were randomly assigned to a target systolic blood pressure of <120 mmHg (intensive treatment) or a target of <140 mmHg (standard treatment). A significantly lower rate of the primary composite outcome and all-cause mortality in the intensive-treatment group than in the standard-treatment group was observed. Summaries and overviews of the late-breaking trials, clinical science special report sessions, and sessions to which members of the Japanese Circulation Society contributed are presented.
authors.affiliation: Department of Cardiology, Keio University School of Medicine.
authors.forename: Yoshiyasu
authors.initials: Y
authors.lastname: Aizawa
authors.forename: Mai
authors.initials: M
authors.lastname: Kimura
authors.forename: Takashi
authors.initials: T
authors.lastname: Kohno
authors.forename: Jun
authors.initials: J
authors.lastname: Fujita
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fukuda
mesh_terms: D000572:American Heart Association; D002318:Cardiovascular Diseases / Q000378:metabolism / Q000401:mortality / Q000503:physiopathology / Q000628:therapy; D003226:Congresses as Topic; D048909:Diabetes Complications / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000503:physiopathology / Q000628:therapy; D005431:Florida; D006801:Humans; D012307:Risk Factors; D014481:United States